JP2018062477A - Fat accumulation inhibitor and food and drink containing the same - Google Patents
Fat accumulation inhibitor and food and drink containing the same Download PDFInfo
- Publication number
- JP2018062477A JP2018062477A JP2016200691A JP2016200691A JP2018062477A JP 2018062477 A JP2018062477 A JP 2018062477A JP 2016200691 A JP2016200691 A JP 2016200691A JP 2016200691 A JP2016200691 A JP 2016200691A JP 2018062477 A JP2018062477 A JP 2018062477A
- Authority
- JP
- Japan
- Prior art keywords
- fat accumulation
- moringa
- solvent extract
- fat
- accumulation inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009825 accumulation Methods 0.000 title claims abstract description 38
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- 235000013305 food Nutrition 0.000 title abstract description 9
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 48
- 230000004069 differentiation Effects 0.000 claims abstract description 26
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 23
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 241000220215 Moringa Species 0.000 claims description 48
- 210000000229 preadipocyte Anatomy 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 244000179886 Moringa oleifera Species 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 35
- 235000019197 fats Nutrition 0.000 description 34
- 239000002904 solvent Substances 0.000 description 32
- 239000002609 medium Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 101000904460 Encephalitozoon cuniculi (strain GB-M1) Probable glycerol-3-phosphate dehydrogenase Proteins 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 108010016731 PPAR gamma Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000000536 PPAR gamma Human genes 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000012192 staining solution Substances 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RDSUFEJPLMOUOL-UHFFFAOYSA-N 1-(2-methylpropyl)-3,7-dihydropurine-2,6-dione Chemical compound O=C1N(CC(C)C)C(=O)NC2=C1NC=N2 RDSUFEJPLMOUOL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003540 anti-differentiation Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
本発明は脂肪蓄積抑制剤に関する。より詳しくは、モリンガの抽出物を有効成分とする脂肪蓄積抑制剤に関する。 The present invention relates to a fat accumulation inhibitor. More specifically, the present invention relates to a fat accumulation inhibitor containing a Moringa extract as an active ingredient.
近年、日本では、食生活、運動習慣、喫煙、飲酒などの生活習慣により引き起こされる生活習慣病が問題となっている。例えば、食習慣が理由で発症する生活習慣病としては、糖尿病、肥満症、高脂血症、高血圧症、大腸がん、歯周病などがある。なかでも、糖尿病、肥満症、高脂血症、高血圧症と言った生活習慣病は、患者数が多いことに加えて、脳梗塞や心筋梗塞の原因となる動脈硬化症の発症と密接に関連していることから特に注目されている。 In recent years, lifestyle-related diseases caused by lifestyle habits such as eating habits, exercise habits, smoking, and drinking have become a problem in Japan. For example, lifestyle-related diseases that develop due to dietary habits include diabetes, obesity, hyperlipidemia, hypertension, colon cancer, and periodontal disease. In particular, lifestyle-related diseases such as diabetes, obesity, hyperlipidemia, and hypertension are closely related to the onset of arteriosclerosis that causes cerebral infarction and myocardial infarction in addition to the large number of patients. Has attracted particular attention.
肥満にはお腹に脂肪がたまる内臓脂肪型肥満(内臓脂肪蓄積)があるが、内臓脂肪蓄積があると、糖尿病や高脂血症・高血圧などがおこりやすくなることがわかっている。しかも、これらが重複し、さらにその数が多くなるほど、動脈硬化を進行させるリスクが高まることもわかっている。そこで、内臓脂肪型肥満に高血糖、高血圧および脂質異常症のうち2つ以上が重なっている状態をメタボリックシンドロームと定義し、メタボリックシンドロームを早期発見・適切な指導を行うことで、生活習慣病の予防や改善が取り組まれている。 Obesity includes visceral fat-type obesity (visceral fat accumulation) in which fat accumulates in the stomach, but it has been known that visceral fat accumulation tends to cause diabetes, hyperlipidemia, and hypertension. Moreover, it has been found that the risk of advancing arteriosclerosis increases as these overlap and the number increases. Therefore, the condition where two or more of hyperglycemia, hypertension, and dyslipidemia overlap with visceral fat obesity is defined as metabolic syndrome, and early detection of metabolic syndrome and appropriate guidance can help prevent lifestyle-related diseases. Prevention and improvement are being addressed.
ところで、肥満には脂肪細胞が重要な役割を果たしており、脂肪細胞中に蓄えられる油滴の肥大化と新しい脂肪細胞への分化の繰り返しが肥満につながるとされている。この脂肪細胞の肥大化や分化を抑制する物質として、トレハロース(特許文献1)、酢酸又は酢酸塩(特許文献2)、イネ科植物の種子及び/又は地上部茎葉から抽出される成分(特許文献3)などの食品由来成分が報告されており、これらを添加した飲食品も開発されている。 By the way, fat cells play an important role in obesity, and it is said that the enlargement of oil droplets stored in the fat cells and repeated differentiation into new fat cells lead to obesity. As a substance that suppresses the enlargement and differentiation of adipocytes, trehalose (Patent Document 1), acetic acid or acetate (Patent Document 2), a component extracted from the seeds of grasses and / or aboveground foliage (Patent Document) Food-derived ingredients such as 3) have been reported, and foods and drinks to which these are added have also been developed.
しかし、上記物質に限ったことではないが、人によっては体質等の影響で効果が得られにくいこともある。そのため、脂肪蓄積抑制および/または脂肪蓄積量低減(脂肪細胞の肥大化の抑制や分化の抑制)を効果的に行うことができる安全性の高い脂肪蓄積抑制剤の開発が引き続き望まれている。 However, it is not limited to the above substances, but depending on the person, the effect may be difficult to obtain due to the influence of the constitution. Therefore, development of a highly safe fat accumulation inhibitor that can effectively suppress fat accumulation and / or reduce the amount of fat accumulation (inhibition of adipocyte hypertrophy and differentiation) has been desired.
本発明は、上記問題点に鑑みてなされたものである。すなわち、本発明は、脂肪蓄積抑制および/または脂肪蓄積量低減(脂肪細胞の肥大化の抑制や分化の抑制)を効果的に行うことができる安全性の高い脂肪蓄積抑制剤を提供することを目的とする。 The present invention has been made in view of the above problems. That is, the present invention provides a highly safe fat accumulation inhibitor that can effectively perform fat accumulation suppression and / or fat accumulation reduction (inhibition of adipocyte hypertrophy and differentiation). Objective.
本発明者らは、既知の食品について脂肪蓄積抑制および/または脂肪蓄積量低減効果(以下、単に「脂肪蓄積抑制効果」と言う。)について調べた。そして、整腸作用が既に知られているモリンガを有機溶媒抽出した物には脂肪蓄積抑制効果があることを新たに見出し、本発明を完成するに至った。 The present inventors investigated fat accumulation suppression and / or fat accumulation reduction effect (hereinafter simply referred to as “fat accumulation suppression effect”) for known foods. And it discovered newly that the thing which extracted the organic solvent from the moringa already known to have an intestinal regulating action has an effect of suppressing fat accumulation, and completed the present invention.
上記課題解決のため、本発明は、モリンガの有機溶媒抽出物を有効成分とする脂肪蓄積抑制剤を提供する。 In order to solve the above-mentioned problems, the present invention provides a fat accumulation inhibitor comprising an organic solvent extract of Moringa as an active ingredient.
また、前記した構成において、モリンガの有機溶媒抽出物濃度が100〜1000μg/mlであることが好ましい。さらに、脂肪前駆細胞から脂肪細胞への分化抑制能を有することが好ましい。 In the above-described configuration, the organic solvent extract concentration of Moringa is preferably 100 to 1000 μg / ml. Furthermore, it preferably has an ability to suppress differentiation from preadipocytes to adipocytes.
さらには、前記した脂肪蓄積抑制剤を含有する飲食品であることが好ましい。 Furthermore, it is preferable that it is food-drinks containing the above-mentioned fat accumulation inhibitor.
本発明によれば、既に公知の食材を原料にすることから、安全性を確保することができる。また、脂肪蓄積抑制効果を有する新たな食材を見出すことにより、摂取者が選択する脂肪蓄積抑制剤の選択肢を増やすことができる。 According to the present invention, since a known food is used as a raw material, safety can be ensured. Moreover, the choice of the fat accumulation inhibitor which an ingestor selects can be increased by finding the new foodstuff which has a fat accumulation inhibitory effect.
以下、本発明の好適な実施形態について説明する。 Hereinafter, preferred embodiments of the present invention will be described.
モリンガは生あるいは乾燥物いずれの形態でもよく、そのまま抽出操作に供してもよいし、必要に応じて切断、粉砕して抽出操作に供することもできる。本発明においては、モリンガの葉を用いるのが好ましく、さらにモリンガの葉の乾燥物を粉砕して用いることが好ましい。 Moringa may be in the form of raw or dried product, and may be used for extraction operation as it is, or may be cut and pulverized for extraction operation as necessary. In the present invention, it is preferable to use moringa leaves, and it is preferable to use pulverized dried moringa leaves.
本発明に用いられるモリンガの有機溶媒抽出物(以下、モリンガ溶媒抽出物という。)は、上記の原料から任意の有機溶媒を用いて抽出して得ることができる。また、抽出には公知の方法が使用できる。 The organic solvent extract of Moringa used in the present invention (hereinafter referred to as Moringa solvent extract) can be obtained by extracting from the above raw materials using an arbitrary organic solvent. A known method can be used for extraction.
抽出に用いられる有機溶媒としては、メタノール、エタノール、n−プロパノール、イソプロパノール、n−ブタノール等の低級アルコール、1,3−ブチレングリコール、プロピレングリコール、グリセリン等の多価アルコールなどの室温で液体であるアルコール類;ジエチルエーテル、プロピルエーテル等のエーテル類;酢酸ブチル、酢酸エチル等のエステル類;アセトン、エチルメチルケトン等のケトン類;ヘキサン、クロロホルム等を挙げることができ、これらの1種または2種以上を用いて抽出を行うことができる。このうち、操作性や環境性の点から、室温で液体であるアルコール類、特に、炭素原子数1〜4の低級アルコールが好ましい。また、残留溶媒による安全性の観点からはエタノールがより好ましい。 The organic solvent used for extraction is liquid at room temperature such as lower alcohols such as methanol, ethanol, n-propanol, isopropanol and n-butanol, and polyhydric alcohols such as 1,3-butylene glycol, propylene glycol and glycerin. Alcohols; ethers such as diethyl ether and propyl ether; esters such as butyl acetate and ethyl acetate; ketones such as acetone and ethyl methyl ketone; hexane, chloroform and the like, and one or two of these Extraction can be performed using the above. Among these, alcohols that are liquid at room temperature, particularly lower alcohols having 1 to 4 carbon atoms, are preferable from the viewpoint of operability and environmental properties. Further, ethanol is more preferable from the viewpoint of safety due to the residual solvent.
また、上記有機溶媒以外に、ごま油、サラダ油、パーム油、オリーブ油、ラード、牛脂等の動植物性油脂を用いて抽出を行っても良い。 Moreover, you may extract using animal and vegetable oils and fats, such as sesame oil, salad oil, palm oil, olive oil, lard, and beef tallow, besides the said organic solvent.
具体的な抽出方法としては、例えば、常圧あるいは加圧下で室温あるいは加温した有機溶媒中にモリンガの葉を加え、浸漬や攪拌しながら抽出する方法や、有機溶媒中で還流しながら抽出する方法などが挙げられる。その際、抽出温度は5℃から有機溶媒の沸点以下の温度とするのが好ましく、抽出時間は使用する有機溶媒の種類や抽出条件によっても異なるが、30分〜72時間程度とするのが好ましい。還流操作により抽出を行う場合は、モリンガの溶媒抽出物が変性や熱分解を起こさないように低沸点の有機溶媒を用いるのが好ましい。 As a specific extraction method, for example, Moringa leaves are added to an organic solvent heated at room temperature or under normal pressure or under pressure, and extracted while being immersed or stirred, or extracted while refluxing in an organic solvent. The method etc. are mentioned. At that time, the extraction temperature is preferably 5 ° C. to the boiling point of the organic solvent, and the extraction time is preferably about 30 minutes to 72 hours, although it varies depending on the type of organic solvent used and the extraction conditions. . When performing extraction by refluxing, it is preferable to use an organic solvent having a low boiling point so that the solvent extract of Moringa does not denature or undergo thermal decomposition.
このようにして得られた抽出液をそのままモリンガの溶媒抽出物として用いてもよい。また、必要に応じて濃縮あるいは凍結乾燥やスプレードライなどの方法により、乾燥、粉末化して、モリンガ溶媒抽出物として使用してもよい。 The extract thus obtained may be used as it is as a solvent extract of Moringa. Further, if necessary, it may be dried and powdered by a method such as concentration or freeze-drying or spray-drying and used as a Moringa solvent extract.
具体的な乾燥方法としては、モリンガ溶媒抽出物が変性や熱分解を起こさない条件であればどのような方法でもよく、例えば、濾過、遠心分離、遠心濾過、スプレードライ、スプレークール、ドラムドライ、真空乾燥、凍結乾燥等が挙げられる。これらの方法を単独または組み合わせて用いることができる。 As a specific drying method, any method may be used as long as the Moringa solvent extract does not cause denaturation or thermal decomposition. For example, filtration, centrifugation, centrifugal filtration, spray drying, spray cooling, drum drying, Examples include vacuum drying and freeze-drying. These methods can be used alone or in combination.
なお、上記モリンガ溶媒抽出物は、食経験のあるモリンガを原料としており、安全性が高く、風味もよいことから、そのまま単独でも摂取することが可能であり、後述する脂肪蓄積抑制剤として長期間の継続的摂取が容易である。 The above moringa solvent extract is made from moringa with food experience, and is safe and good in flavor, so it can be taken alone as it is, and it can be used for a long time as a fat accumulation inhibitor described later. Is easy to take continuously.
モリンガ溶媒抽出物は、そのまま単独で脂肪蓄積抑制剤として摂取してもよい。ここで、摂取するモリンガ溶媒抽出物濃度としては100〜1000μg/mlが好ましく、100〜750μg/mlがより好ましく、100〜500μg/mlがさらにより好ましい。また、本発明の効果を阻害しない限り、モリンガ溶媒抽出物に、添加剤、他の公知の脂肪蓄積抑制物質、脂肪分解促進物質、脂肪代謝改善物質等を単独または複数組み合わせて配合してもよい。 Moringa solvent extract may be taken alone as a fat accumulation inhibitor. Here, the concentration of the Moringa solvent extract to be ingested is preferably 100 to 1000 μg / ml, more preferably 100 to 750 μg / ml, and even more preferably 100 to 500 μg / ml. Further, as long as the effects of the present invention are not inhibited, additives, other known fat accumulation suppressing substances, lipolysis promoting substances, fat metabolism improving substances, etc. may be added to Moringa solvent extract alone or in combination. .
本発明の脂肪蓄積抑制剤の剤形としては、例えば、錠剤、カプセル剤、顆粒剤、散剤、シロップ剤、ドライシロップ剤、液剤、懸濁剤、吸入剤などが挙げられる。 Examples of the dosage form of the fat accumulation inhibitor of the present invention include tablets, capsules, granules, powders, syrups, dry syrups, solutions, suspensions, inhalants and the like.
脂肪蓄積抑制剤を含有する飲食品としては特に制限されず、例えば、飲料、スプレッド類、ドレッシング類、パン類、米飯類、麺類、ソース類、菓子などが挙げられる。 It does not restrict | limit especially as food / beverage products containing a fat accumulation inhibitor, For example, a drink, spreads, dressings, breads, cooked rice, noodles, sauces, confectionery, etc. are mentioned.
本発明の飲食品は、各種栄養素、各種ビタミン、ミネラル、食物繊維、種々の添加剤をさらに配合することができる。 The food and drink of the present invention can further contain various nutrients, various vitamins, minerals, dietary fiber, and various additives.
以下、実施例に基づいて本発明をさらに具体的に説明する。 Hereinafter, the present invention will be described more specifically based on examples.
本実施例で用いるモリンガの葉の有機溶媒抽出物は次のようにして得た。市販のモリンガ葉粉末(日本粉末薬品株式会社製;商品名「モリンガ末」)10gにエタノール200mlを加え、10分間超音波処理をした後、30分間振とう処理した。次に、一晩浸漬した後、浸漬液をろ紙でろ過した。ろ液をエバポレータで濃縮して抽出物約1gを得た。この抽出物をエタノールに溶解させ、500mg/mlの濃度になるように希釈した。 The organic solvent extract of Moringa leaves used in this example was obtained as follows. 200 ml of ethanol was added to 10 g of commercially available Moringa leaf powder (manufactured by Nippon Powder Chemical Co., Ltd .; trade name “Moringa powder”), subjected to ultrasonic treatment for 10 minutes, and then shaken for 30 minutes. Next, after being immersed overnight, the immersion liquid was filtered with a filter paper. The filtrate was concentrated with an evaporator to obtain about 1 g of an extract. This extract was dissolved in ethanol and diluted to a concentration of 500 mg / ml.
『試験1:脂肪蓄積抑制作用確認試験(Oil Red O染色)』
モリンガ溶媒抽出物に脂肪蓄積抑制効果があるかについて、Oil Red O染色により確認した。Oil Red O染色液で細胞内の脂肪滴を染色して吸光度測定することで、細胞中に蓄積されている脂肪量の測定が行える。
"Test 1: Fat accumulation suppression action confirmation test (Oil Red O staining)"
Whether the Moringa solvent extract has an effect of inhibiting fat accumulation was confirmed by Oil Red O staining. The amount of fat accumulated in the cells can be measured by staining the lipid droplets in the cells with Oil Red O staining solution and measuring the absorbance.
まず、Oil Red O染色液原液を調整した。具体的には、Oil Red O染色液粉末0.15gを2−プロパノール50mlに溶解した。次に、3,000rpmで5分間程度遠心分離した。最後に、上清を0.2〜0.45μmのシリンジフィルターでろ過することで、原液を得た。測定時には、原液6mlに水4mlを加えて1時間静置後、0.2〜0.45μmのシリンジフィルターで濾過したものを染色液として用いた。 First, a stock solution of Oil Red O staining solution was prepared. Specifically, 0.15 g of Oil Red O staining solution powder was dissolved in 50 ml of 2-propanol. Next, it was centrifuged at 3,000 rpm for about 5 minutes. Finally, the supernatant was filtered through a 0.2-0.45 μm syringe filter to obtain a stock solution. At the time of measurement, 4 ml of water was added to 6 ml of the stock solution, allowed to stand for 1 hour, and then filtered through a 0.2-0.45 μm syringe filter as the staining solution.
細胞については、脂肪前駆細胞である3T3−L1細胞(ATCC)を、12ウェルプレートに播種し、10%NBCS添加DMEM培地で2日間培養した後、分化誘導培地(0.5mM 1−メチル−3−イソブチルキサンチン、0.25μM デキサメタゾン、10μg/ml インスリンを含む10%NBCS添加DMEM培地)で2日間培養し、脂肪細胞に分化誘導した。その後、成熟促進培地(10μg/ml インスリンを含む10%NBCS添加DMEM培地)に変えて7日間培養した。この際、上記分化誘導培地および成熟促進培地に、モリンガ溶媒抽出物を0、20、50、100、250μg/mlとなるように添加した。 As for the cells, 3T3-L1 cells (ATCC), which are preadipocytes, were seeded in a 12-well plate, cultured in DMEM medium supplemented with 10% NBCS for 2 days, and then differentiation induction medium (0.5 mM 1-methyl-3). -10% NBCS-added DMEM medium containing isobutylxanthine, 0.25 μM dexamethasone, 10 μg / ml insulin) for 2 days to induce differentiation into adipocytes. Thereafter, the medium was changed to a maturation promoting medium (10% NBCS-added DMEM medium containing 10 μg / ml insulin) and cultured for 7 days. At this time, Moringa solvent extract was added to the differentiation induction medium and the maturation promotion medium at 0, 20, 50, 100, and 250 μg / ml.
続いて、培養液を除去し、10%ホルマリン溶液を500μl/ウェルで添加した。ホルマリン溶液添加してから1時間放置し、細胞をウェル上に固定した。ホルマリン除去後、蒸留水で洗浄し、Oil Red O染色液を300μl/ウェルで添加した。室温で15分間静置し、細胞内の脂肪を染色した。染色液除去後、蒸留水で細胞を洗浄した。最後に、2−プロパノールを500μl/ウェルで添加し、細胞から色素を抽出した。そして、抽出液の吸光度をプレートリーダー(490nm)で測定した。 Subsequently, the culture solution was removed, and 10% formalin solution was added at 500 μl / well. The formalin solution was added and left for 1 hour to fix the cells on the wells. After removing formalin, the plate was washed with distilled water, and Oil Red O staining solution was added at 300 μl / well. The mixture was allowed to stand at room temperature for 15 minutes to stain intracellular fat. After removing the staining solution, the cells were washed with distilled water. Finally, 2-propanol was added at 500 μl / well to extract the dye from the cells. Then, the absorbance of the extract was measured with a plate reader (490 nm).
結果を、表1に示す。なお、測定結果はモリンガ溶媒抽出物添加量が0μg/mlの吸光度を100としたときの相対値で示す。 The results are shown in Table 1. The measurement result is shown as a relative value when the absorbance when the Moringa solvent extract addition amount is 0 μg / ml is taken as 100.
表1から明らかなように、モリンガ溶媒抽出物を添加することによって、細胞内の脂肪量が減少していることがわかる。モリンガ溶媒抽出物の濃度が100μg/ml以上では濃度に比例して細胞中の脂肪量減っており、濃度が250μg/mlでは、細胞中の脂肪量はモリンガ溶媒抽出物無添加の場合に比べて約半分の量に減っていた。 As is clear from Table 1, it can be seen that the amount of fat in the cells is reduced by adding the Moringa solvent extract. When the concentration of the Moringa solvent extract is 100 μg / ml or more, the amount of fat in the cell decreases in proportion to the concentration, and when the concentration is 250 μg / ml, the amount of fat in the cell is lower than when no Moringa solvent extract is added. The amount was reduced to about half.
『試験2:脂肪細胞への分化に関わる遺伝子発現量確認試験(PPARγの発現量確認)』
Oil Red O染色の結果が、脂肪細胞への脂肪蓄積抑制によるものか、脂肪細胞へ分化抑制によるものかについて、PPARγの発現量について確認を行った。ここで、PPARγは脂肪細胞分化のマスターレギュレーターとして知られている。
“Test 2: Confirmation of expression level of genes involved in differentiation into adipocytes (Confirmation of expression level of PPARγ)”
The expression level of PPARγ was confirmed as to whether the result of Oil Red O staining was due to suppression of fat accumulation in fat cells or suppression of differentiation into fat cells. Here, PPARγ is known as a master regulator of adipocyte differentiation.
まず、3T3−L1細胞(ATCC)を、12ウェルプレートに播種し、10%NBCS添加DMEM培地で2日間培養した後、分化誘導培地(0.5mM 1−メチル−3−イソブチルキサンチン、0.25μM デキサメタゾン、10μg/ml インスリンを含む10%NBCS添加DMEM培地)で2日間培養し、脂肪細胞に分化誘導した。その後、成熟促進培地(10μg/mlインスリンを含む10%NBCS添加DMEM培地)に変えて7日間培養した。この際、上記分化誘導培地および成熟促進培地に、モリンガ溶媒抽出物を0、20、50、100、250μg/mlとなるように添加した。 First, 3T3-L1 cells (ATCC) were seeded in a 12-well plate, cultured in DMEM medium supplemented with 10% NBCS for 2 days, and then differentiation induction medium (0.5 mM 1-methyl-3-isobutylxanthine, 0.25 μM). Dexamethasone, 10% NBCS-added DMEM medium containing 10 μg / ml insulin) was cultured for 2 days to induce differentiation into adipocytes. Thereafter, the medium was changed to a maturation promoting medium (10% NBCS-added DMEM medium containing 10 μg / ml insulin) and cultured for 7 days. At this time, Moringa solvent extract was added to the differentiation induction medium and the maturation promotion medium at 0, 20, 50, 100, and 250 μg / ml.
次に、各培養細胞からTotal RNAを調製し、逆転写反応によりcDNAを得た。得られたcDNAを鋳型として、LightCycler(ロシュ・ライフサイエンス社)を用いた定量的PCRによりPPARγ遺伝子の発現量を測定した。測定したPPARγ遺伝子の発現量は、内部標準(βアクチン遺伝子発現量)により補正した。 Next, total RNA was prepared from each cultured cell, and cDNA was obtained by reverse transcription reaction. Using the obtained cDNA as a template, the expression level of the PPARγ gene was measured by quantitative PCR using LightCycler (Roche Life Science). The measured expression level of the PPARγ gene was corrected by an internal standard (β-actin gene expression level).
結果を表2に示す。なお、測定結果はモリンガ溶媒抽出物添加量が0μg/mlの発現量を100としたときの相対値で示す。 The results are shown in Table 2. The measurement results are shown as relative values when the expression level when the Moringa solvent extract addition amount is 0 μg / ml is 100.
表2から明らかなように、モリンガ溶媒抽出物の添加濃度が50μg/mlまでは、PPARγの遺伝子発現量に変化が見られなかった。しかしながら、モリンガ溶媒抽出物の添加濃度が100μg/ml以上になるとPPRAγの遺伝子発現量に低下が認められ、250μg/mlになるとPPRAγの遺伝子発現量は添加していないものの約1/3以下となった。以上のことから、モリンガ溶媒抽出物は100μg/ml以上の濃度において、脂肪細胞の分化を抑制していることが示唆された。 As is clear from Table 2, no change was observed in the gene expression level of PPARγ until the addition concentration of Moringa solvent extract was 50 μg / ml. However, when the addition concentration of the Moringa solvent extract is 100 μg / ml or more, a decrease in the gene expression level of PPRAγ is observed, and when it is 250 μg / ml, the gene expression level of PPRAγ is about 3 or less of that not added. It was. From the above, it was suggested that the Moringa solvent extract suppressed adipocyte differentiation at a concentration of 100 μg / ml or more.
『試験3:脂肪前駆細胞の分化抑制活性確認試験(GPDH活性)』
試験2の結果に基づき、脂肪前駆細胞から脂肪細胞への分化が実際に抑制されているかについて確認を行った。ここでGPDH活性は脂肪前駆細胞が脂肪細胞に分化した際に急増することが知られている。
“Test 3: Anti-differentiation activity confirmation test of preadipocytes (GPDH activity)”
Based on the result of Test 2, it was confirmed whether differentiation from preadipocytes to adipocytes was actually suppressed. Here, it is known that GPDH activity increases rapidly when preadipocytes differentiate into adipocytes.
まず、3T3−L1細胞(ATCC)を、12ウェルプレートに播種し、10%NBCS添加DMEM培地で2日間培養した後、分化誘導培地(0.5mM 1−メチル−3−イソブチルキサンチン、0.25μM デキサメタゾン、10μg/ml インスリンを含む10%NBCS添加DMEM培地)で2日間培養し、脂肪細胞に分化誘導した。その後、成熟促進培地(10μg/ml インスリンを含む10%NBCS添加DMEM培地)に変えて7日間培養した。この際、上記分化誘導培地および成熟促進培地に、モリンガ溶媒抽出物を0、20、50、100、250μg/mlとなるように添加した。 First, 3T3-L1 cells (ATCC) were seeded in a 12-well plate, cultured in DMEM medium supplemented with 10% NBCS for 2 days, and then differentiation induction medium (0.5 mM 1-methyl-3-isobutylxanthine, 0.25 μM). Dexamethasone, 10% NBCS-added DMEM medium containing 10 μg / ml insulin) was cultured for 2 days to induce differentiation into adipocytes. Thereafter, the medium was changed to a maturation promoting medium (10% NBCS-added DMEM medium containing 10 μg / ml insulin) and cultured for 7 days. At this time, Moringa solvent extract was added to the differentiation induction medium and the maturation promotion medium at 0, 20, 50, 100, and 250 μg / ml.
次に、培養細胞の培養液を除去し、PBS(−)で2回洗浄した。そして、酵素抽出液を0.5ml加え、ピペッティングにより、細胞をウェルから剥がした。剥がした細胞をサンプリングチューブに酵素抽出液ごと入れ、このサンプリングチューブを10,000rpm、4℃で、5分間遠心分離し、上清を回収した。 Next, the culture broth of the cultured cells was removed and washed twice with PBS (−). Then, 0.5 ml of the enzyme extract was added, and the cells were detached from the well by pipetting. The peeled cells were put together with the enzyme extract into a sampling tube, and this sampling tube was centrifuged at 10,000 rpm and 4 ° C. for 5 minutes, and the supernatant was collected.
次に、GPDH測定キット(タカラバイオ株式会社)の反応基質溶液100μlを96ウェルプレートに入れ、30℃で約30分間加温した。加温後、ウェルに各上清を25μl加え、よく撹拌した。撹拌後、プレートリーダー(340nm)で吸光度を1分おきに10分間測定した。そして、得られた測定値から1分間当たりの吸光度の変化量(ΔO.D.(340nm)/分)を求めた。得られた吸光度の変化量を下記式に当てはめ、GPDH活性を決定した。 Next, 100 μl of a reaction substrate solution of GPDH measurement kit (Takara Bio Inc.) was placed in a 96-well plate and heated at 30 ° C. for about 30 minutes. After warming, 25 μl of each supernatant was added to the well and stirred well. After stirring, the absorbance was measured every other minute for 10 minutes with a plate reader (340 nm). Then, the amount of change in absorbance per minute (ΔOD (340 nm) / min) was determined from the obtained measured values. The obtained change in absorbance was applied to the following formula to determine GPDH activity.
GPDH活性(U/ml)=ΔO.D.(340nm)/分×2.06 GPDH activity (U / ml) = ΔO. D. (340 nm) /min×2.06
その結果を、表3に示す。なお、測定結果はモリンガ溶媒抽出物添加量0μg/mlのGDPH活性を100としたときの相対値も併せて示す。 The results are shown in Table 3. The measurement results also show the relative value when the GDPH activity of Moringa solvent extract addition amount 0 μg / ml is taken as 100.
表3から明らかなように、モリンガ溶媒抽出物の添加濃度が50μg/mlまでは、GPDH活性に変化が見られなかった。しかしながら、モリンガ溶媒抽出物の添加濃度が100μg/ml以上になるとGPDH活性に低下が認められた。さらに、250μg/mlになるとGPDH活性がほぼないという結果になった。表3の結果は表2の傾向と似ており、PPARγの発現率低下に伴いGPDH活性も低下していることがわかる。したがって、モリンガ溶媒抽出物は100μg/ml以上の濃度において、脂肪細胞の分化を抑制していることがこの試験においても明らかとなった。 As is clear from Table 3, no change was observed in GPDH activity until the addition concentration of Moringa solvent extract was 50 μg / ml. However, when the addition concentration of Moringa solvent extract was 100 μg / ml or more, a decrease in GPDH activity was observed. Furthermore, when the concentration was 250 μg / ml, there was almost no GPDH activity. The results in Table 3 are similar to the trends in Table 2, and it can be seen that GPDH activity is reduced with the decrease in the expression rate of PPARγ. Therefore, it was also revealed in this test that Moringa solvent extract suppressed adipocyte differentiation at a concentration of 100 μg / ml or more.
試験2および試験3の結果から、モリンガ溶媒抽出物の濃度が100μg/ml以上における試験1の結果は、PPRAγの遺伝子発現量が減少したことに伴う脂肪細胞への分化抑制が主な原因と考えられる。しかし、PPARγの遺伝子発現量およびGPDH活性に差が認められなかった20μg/ml及び50μg/mlにおいても、試験1では細胞内の脂肪量が減少している。このことから、モリンガ溶媒抽出物には、PPARγ遺伝子の発現量を低下させるだけでなく、細胞内への脂肪の蓄積を抑制する効果があるものと推察される。 From the results of Test 2 and Test 3, the result of Test 1 when the concentration of Moringa solvent extract is 100 μg / ml or more is considered to be mainly due to the suppression of differentiation into adipocytes accompanying the decrease in the expression level of PPRAγ gene. It is done. However, even in 20 μg / ml and 50 μg / ml in which no difference was found in the gene expression level of PPARγ and GPDH activity, the amount of intracellular fat decreased in Test 1. From this, it is presumed that the Moringa solvent extract not only reduces the expression level of the PPARγ gene, but also has the effect of suppressing the accumulation of fat in the cells.
『試験4:安全性確認試験』 “Test 4: Safety confirmation test”
最後に、モリンガ溶媒抽出物の安全性について確認を行った。安全性については分化細胞および未分化細胞それぞれについて試験を行った。 Finally, the safety of the Moringa solvent extract was confirmed. For safety, each of differentiated cells and undifferentiated cells was tested.
(分化細胞の生存率)
まず、3T3−L1細胞(ATCC)を、12ウェルプレートに播種し、10%NBCS添加DMEM培地で2日間培養した後、分化誘導培地(0.5mM 1−メチル−3−イソブチルキサンチン、0.25μM デキサメタゾン、10μg/ml インスリンを含む10%NBCS添加DMEM培地)で2日間培養し、脂肪細胞に分化誘導した。その後、成熟促進培地(10μg/ml インスリンを含む10%NBCS添加DMEM培地)に変えて7日間培養した。次に、セルカウンティングキット(同仁化学研究所製)を20μl/ウェルとなるように添加した。また、モリンガ溶媒抽出物の濃度が0、20、50、100、250μg/mlとなるように各ウェルに添加した。そして、37℃で4時間培養した後、プレートリーダー(450nm)で吸光度を測定した。
(Viability of differentiated cells)
First, 3T3-L1 cells (ATCC) were seeded in a 12-well plate, cultured in DMEM medium supplemented with 10% NBCS for 2 days, and then differentiation induction medium (0.5 mM 1-methyl-3-isobutylxanthine, 0.25 μM). Dexamethasone, 10% NBCS-added DMEM medium containing 10 μg / ml insulin) was cultured for 2 days to induce differentiation into adipocytes. Thereafter, the medium was changed to a maturation promoting medium (10% NBCS-added DMEM medium containing 10 μg / ml insulin) and cultured for 7 days. Next, a cell counting kit (manufactured by Dojindo Laboratories) was added at 20 μl / well. Moreover, it added to each well so that the density | concentration of a moringa solvent extract might be 0, 20, 50, 100, 250 microgram / ml. And after culturing at 37 degreeC for 4 hours, the light absorbency was measured with the plate reader (450 nm).
(未分化細胞の生存率)
まず、3T3−L1細胞(ATCC)を、12ウェルプレートに播種し、10%NBCS添加DMEM培地で2日間培養した。次に、セルカウンティングキット(同仁化学研究所製)を20μl/ウェルとなるように添加した。また、モリンガ溶媒抽出物の濃度が0、20、50、100、250μg/mlとなるように各ウェルに添加した。そして、37℃で4時間培養した後、プレートリーダー(450nm)で吸光度を測定した。
(Viability of undifferentiated cells)
First, 3T3-L1 cells (ATCC) were seeded in a 12-well plate and cultured in DMEM medium supplemented with 10% NBCS for 2 days. Next, a cell counting kit (manufactured by Dojindo Laboratories) was added at 20 μl / well. Moreover, it added to each well so that the density | concentration of a moringa solvent extract might be 0, 20, 50, 100, 250 microgram / ml. And after culturing at 37 degreeC for 4 hours, the light absorbency was measured with the plate reader (450 nm).
結果を表4に示す。なお、測定結果はモリンガ溶媒抽出物添加量が0μg/mlの細胞生存率を100としたときの相対値で示す。 The results are shown in Table 4. In addition, a measurement result is shown by a relative value when the cell viability when the addition amount of the Moringa solvent extract is 0 μg / ml is 100.
表4から明らかなように、モリンガ溶媒抽出物を添加しても、各濃度における分化細胞および未分化細胞の生存率は高いままであった。したがって、安全性に問題ないことがわかる。 As is apparent from Table 4, even when Moringa solvent extract was added, the viability of differentiated cells and undifferentiated cells at each concentration remained high. Therefore, it turns out that there is no problem in safety.
以上説明したように、モリンガの葉のエタノール抽出物には、脂肪前駆細胞から脂肪細胞への分化を抑制するという新規な効果が認められた。これにより、既に公知の食材を原料にすることから、安全性を確保するとともに、摂取者が選択する脂肪蓄積抑制剤の選択肢を増やすことができる。 As explained above, the Moringa leaf ethanol extract was found to have a novel effect of suppressing the differentiation of preadipocytes into adipocytes. Thereby, since a well-known foodstuff is used as a raw material, while ensuring safety | security, the choice of the fat accumulation inhibitor which an ingestor selects can be increased.
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016200691A JP2018062477A (en) | 2016-10-12 | 2016-10-12 | Fat accumulation inhibitor and food and drink containing the same |
PCT/JP2017/036076 WO2018070312A1 (en) | 2016-10-12 | 2017-10-04 | Fat accumulation inhibitor, and food and beverage containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016200691A JP2018062477A (en) | 2016-10-12 | 2016-10-12 | Fat accumulation inhibitor and food and drink containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018062477A true JP2018062477A (en) | 2018-04-19 |
Family
ID=61905475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016200691A Pending JP2018062477A (en) | 2016-10-12 | 2016-10-12 | Fat accumulation inhibitor and food and drink containing the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2018062477A (en) |
WO (1) | WO2018070312A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009066303A2 (en) * | 2007-11-22 | 2009-05-28 | Ganga Raju Gokaraju | New synergistic phytochemical composition for the treatment of obesity |
JP2010503729A (en) * | 2006-09-26 | 2010-02-04 | コングック ユニヴァーシティ インダストリアル コーペレーション コーポレーション | Pharmaceutical composition for obesity treatment and prevention containing cordycepin |
JP2014208608A (en) * | 2013-03-22 | 2014-11-06 | ライオン株式会社 | Glucose metabolism improving agent |
WO2015066339A1 (en) * | 2013-11-01 | 2015-05-07 | Rutgers, The State University Of New Jersey | Extracts from plants of the moringaceae family and methods of making |
JP2016060736A (en) * | 2014-09-22 | 2016-04-25 | ライオン株式会社 | Carbohydrate metabolism improving agent |
WO2017073473A1 (en) * | 2015-10-28 | 2017-05-04 | 太陽化学株式会社 | Moringa extract |
-
2016
- 2016-10-12 JP JP2016200691A patent/JP2018062477A/en active Pending
-
2017
- 2017-10-04 WO PCT/JP2017/036076 patent/WO2018070312A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503729A (en) * | 2006-09-26 | 2010-02-04 | コングック ユニヴァーシティ インダストリアル コーペレーション コーポレーション | Pharmaceutical composition for obesity treatment and prevention containing cordycepin |
WO2009066303A2 (en) * | 2007-11-22 | 2009-05-28 | Ganga Raju Gokaraju | New synergistic phytochemical composition for the treatment of obesity |
JP2014208608A (en) * | 2013-03-22 | 2014-11-06 | ライオン株式会社 | Glucose metabolism improving agent |
WO2015066339A1 (en) * | 2013-11-01 | 2015-05-07 | Rutgers, The State University Of New Jersey | Extracts from plants of the moringaceae family and methods of making |
JP2016060736A (en) * | 2014-09-22 | 2016-04-25 | ライオン株式会社 | Carbohydrate metabolism improving agent |
WO2017073473A1 (en) * | 2015-10-28 | 2017-05-04 | 太陽化学株式会社 | Moringa extract |
Non-Patent Citations (3)
Title |
---|
AHMED, HANAA H. ET AL.: "Moringa oleifera offers a multi-mechanistic approach for management of obesity in rats", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH, vol. 29, no. 2, JPN6017042432, 2014, pages 98 - 106, XP055475813, ISSN: 0004385287 * |
FOOD AND NUTRITION SCIENCES, vol. 2, JPN6020043480, 2011, pages 809 - 817, ISSN: 0004385288 * |
GENETICS AND MOLECULAR RESEARCH, vol. 13, no. 1, JPN6020043483, 2014, pages 723 - 735, ISSN: 0004385289 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018070312A1 (en) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kwan et al. | The anticancer and antiobesity effects of Mediterranean diet | |
Kondo et al. | Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation | |
Park et al. | Lactobacillus plantarum LG42 isolated from gajami sik‐hae inhibits adipogenesis in 3T3‐L1 adipocyte | |
Lee et al. | Mulberry fruit extract ameliorates adipogenesis via increasing AMPK activity and downregulating microRNA-21/143 in 3T3-L1 adipocytes | |
Langner et al. | Melanoidins isolated from heated potato fiber (Potex) affect human colon cancer cells growth via modulation of cell cycle and proliferation regulatory proteins | |
JP2023157951A (en) | Composition for improving liver function | |
JP3671190B1 (en) | Extract obtained from lotus plant, method for producing the extract and anti-obesity agent | |
JP6599592B2 (en) | α-Glucosidase activity inhibitor | |
JP2006335741A (en) | Peroxisome proliferating agent-responsive receptor ligand composition derived from plant belonging to genus amorphophallus | |
Pan et al. | Anti‐obesity effect of fermented lemon peel on high‐fat diet‐induced obese mice by modulating the inflammatory response | |
JP2008189681A (en) | Lipid metabolism improving agent | |
JP2016132641A (en) | Food taking method | |
WO2013129334A1 (en) | AGONIST THAT MIMICS MOTIONAL EFFECT, AND CO-ACTIVATOR FOR AMPK AND PPARδ | |
JPWO2016006548A1 (en) | PPARγ activator, anti-obesity agent and anti-diabetic agent | |
JP6847511B2 (en) | Fat accumulation inhibitor and foods and drinks containing it | |
JP2018062477A (en) | Fat accumulation inhibitor and food and drink containing the same | |
Sekiya et al. | Neoxanthin in young vegetable leaves prevents fat accumulation in differentiated adipocytes | |
JP5947047B2 (en) | PPAR activator | |
JP2012171911A (en) | Ppar-activating agent | |
JP2009102288A (en) | Fat accumulation inhibitor | |
JP6131164B2 (en) | PPAR activator and composition thereof | |
JP2009249331A (en) | Plant-originated agent for preventing or ameliorating hyperlipemia | |
JP2009235068A (en) | Ppar activator | |
JP2015020993A (en) | Inflammation preventive agent | |
JP5346624B2 (en) | PPAR activator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200604 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201117 |